Stocks and Investing
Stocks and Investing
Thu, November 11, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, November 10, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Dane Leone Maintained (BPMC) at Strong Buy with Increased Target to $133 on, Nov 10th, 2021
Dane Leone of Raymond James, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $122 to $133 on, Nov 10th, 2021.
Dane has made no other calls on BPMC in the last 4 months.
There are 2 other peers that have a rating on BPMC. Out of the 2 peers that are also analyzing BPMC, 1 agrees with Dane's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $111 on, Friday, October 29th, 2021
This is the rating of the analyst that currently disagrees with Dane
- Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Thursday, October 28th, 2021
Contributing Sources